Shareholdings
| Concept |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2023-03-31 |
As at 2022-03-31 |
As at 2022-03-31 |
As at 2022-03-31 |
As at 2022-03-31 |
As at 2022-03-31 |
As at 2022-03-31 |
As at 2022-03-31 |
As at 2022-03-31 |
As at 2022-03-31 |
As at 2022-03-31 |
As at 2022-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholdings | ||||||||||||||||||||||
| Reporting company | ||||||||||||||||||||||
| Details of specified investment shares held for purposes other than pure investment | ||||||||||||||||||||||
| Issue |
Roivant Sciences Ltd.
|
㈱メディパルホールディングス
|
Cogstate Ltd.
|
㈱ほくやく・竹山ホールディングス
|
㈱マツキヨココカラ&カンパニー
|
キッセイ薬品工業㈱
|
アルフレッサ
ホールディングス㈱
|
㈱スズケン
|
ライフネット生命保険㈱
|
アステナホールディングス㈱
|
㈱バイタルケーエスケー・ホールディングス
|
— | — | — | — | — | — | — | — | — | — | — |
| Number of shares |
874,957
xbrli:shares
|
134,748
xbrli:shares
|
11,738,243
xbrli:shares
|
546,005
xbrli:shares
|
2,815,000
xbrli:shares
|
474,000
xbrli:shares
|
xbrli:shares
|
100
xbrli:shares
|
349,000
xbrli:shares
|
56,608
xbrli:shares
|
642,154
xbrli:shares
|
129,395
xbrli:shares
|
11,738,243
xbrli:shares
|
1,040,945
xbrli:shares
|
642,154
xbrli:shares
|
xbrli:shares
|
546,005
xbrli:shares
|
2,302,724
xbrli:shares
|
2,815,000
xbrli:shares
|
56,608
xbrli:shares
|
474,000
xbrli:shares
|
874,957
xbrli:shares
|
| Carrying amount |
862,000,000
JPY
|
243,000,000
JPY
|
1,584,000,000
JPY
|
346,000,000
JPY
|
19,733,000,000
JPY
|
1,252,000,000
JPY
|
JPY
|
0
JPY
|
406,000,000
JPY
|
25,000,000
JPY
|
574,000,000
JPY
|
261,000,000
JPY
|
2,484,000,000
JPY
|
3,779,000,000
JPY
|
472,000,000
JPY
|
JPY
|
360,000,000
JPY
|
3,912,000,000
JPY
|
12,203,000,000
JPY
|
25,000,000
JPY
|
1,211,000,000
JPY
|
529,000,000
JPY
|
| Whether issuer of aforementioned shares holds reporting company's shares |
無
|
有
|
無
|
有
|
有
|
有
|
無
|
有
|
無
|
有
|
有
|
— | — | — | — | — | — | — | — | — | — | — |